Stempeutics has inked an out-licensing deal with Cipla, for its stem cell therapy product Stempeucel. It is suggested for treating critical limb ischemia. In a...
Stempeutics Research has got the limited approval from the national drug regulator, DCGI, for its stem cell based product Stempeucel to treat Buerger’s Disease. Cipla,...